Research
Hormonal
Naltrexone/Bupropion combination therapy offers good psychiatric tolerability with only mild, transient anxiety and insomnia, making it a safe alternative for patients concerned about mood stability.
Naltrexone/Bupropion is a well-tolerated weight loss option with a favorable psychiatric profile. While you may experience mild anxiety or insomnia initially, these do not typically progress to serious conditions. It is particularly suitable for patients with emotional eating patterns.
ModerateSupportsMEDIUM confidence
boa tolerabilidade da naltrexona/bupropiona, com efeitos leves de ansiedade e insônia... sem aumento de ideação suicida ou depressão clinicamente significativa.
Why this rating
Based on observational studies and meta-analyses included in the review.
Source
SAÚDE MENTAL NO EMAGRECIMENTO: EFEITOS ADVERSOS DE NOVAS TERAPIAS FARMACOLÓGICAS
Kelli Maria Alvarenga de Macedo et al. · Revista Foco · 2025
DOI 10.54751/revistafoco.v18n11-117
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Multidisciplinary follow-up integrating pharmacotherapy, psychology, and nutrition significantly improves therapeutic adherence, mental health outcomes, and weight loss maintenance compared to pharmacotherapy alone.Good
- GLP-1 agonists (semaglutide, tirzepatide) produce significant weight loss (15-21%) but are associated with isolated reports of depression and suicidal ideation, though causal links remain unproven.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →